Astec LifeSciences Limited (ASTEC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Astec LifeSciences Limited (ASTEC) has a cash flow conversion efficiency ratio of -0.036x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-83.99 Million ≈ $-908.28K USD) by net assets (Rs2.35 Billion ≈ $25.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Astec LifeSciences Limited stock valuation for the company's overall valuation and market capitalisation.
Astec LifeSciences Limited - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Astec LifeSciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Astec LifeSciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Astec LifeSciences Limited ranked by their cash flow conversion efficiency. Explore Astec LifeSciences Limited cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vestel Elektronik Sanayi ve Ticaret AS
IS:VESTL
|
0.049x |
|
Amaero Ltd
AU:3DA
|
-0.190x |
|
Shangri-La Hotel Public Company Limited
BK:SHANG
|
0.013x |
|
Laguna Resorts & Hotels Public Company Limited
BK:LRH
|
0.012x |
|
Kolibri Global Energy Inc
TO:KEI
|
0.033x |
|
BV Financial, Inc. Common Stock
NASDAQ:BVFL
|
0.019x |
|
Aplicaciones y Tratamiento de Sistemas S.A.
MC:ATSI
|
0.029x |
|
Sparebank 1 Nordvest
OL:SNOR
|
-0.029x |
Annual Cash Flow Conversion Efficiency for Astec LifeSciences Limited (2008–2025)
The table below shows the annual cash flow conversion efficiency of Astec LifeSciences Limited from 2008 to 2025. View current stock price of Astec LifeSciences Limited for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs2.35 Billion ≈ $25.42 Million |
Rs-83.99 Million ≈ $-908.28K |
-0.036x | -229.20% |
| 2024-03-31 | Rs3.70 Billion ≈ $39.96 Million |
Rs102.21 Million ≈ $1.11 Million |
0.028x | -84.46% |
| 2023-03-31 | Rs4.20 Billion ≈ $45.37 Million |
Rs746.56 Million ≈ $8.07 Million |
0.178x | +199.02% |
| 2022-03-31 | Rs3.97 Billion ≈ $42.90 Million |
Rs236.04 Million ≈ $2.55 Million |
0.060x | +325.51% |
| 2021-03-31 | Rs3.09 Billion ≈ $33.45 Million |
Rs-81.62 Million ≈ $-882.72K |
-0.026x | -103.87% |
| 2020-03-31 | Rs2.47 Billion ≈ $26.70 Million |
Rs1.68 Billion ≈ $18.22 Million |
0.682x | +805.15% |
| 2019-03-31 | Rs2.03 Billion ≈ $21.93 Million |
Rs152.85 Million ≈ $1.65 Million |
0.075x | -80.20% |
| 2018-03-31 | Rs1.70 Billion ≈ $18.38 Million |
Rs646.75 Million ≈ $6.99 Million |
0.381x | +173.44% |
| 2017-03-31 | Rs1.38 Billion ≈ $14.94 Million |
Rs192.32 Million ≈ $2.08 Million |
0.139x | +401.11% |
| 2016-03-31 | Rs1.17 Billion ≈ $12.65 Million |
Rs-54.05 Million ≈ $-584.56K |
-0.046x | -137.74% |
| 2015-03-31 | Rs1.35 Billion ≈ $14.64 Million |
Rs165.82 Million ≈ $1.79 Million |
0.122x | -21.96% |
| 2014-03-31 | Rs1.14 Billion ≈ $12.28 Million |
Rs178.19 Million ≈ $1.93 Million |
0.157x | +1.12% |
| 2013-03-31 | Rs1.06 Billion ≈ $11.45 Million |
Rs164.31 Million ≈ $1.78 Million |
0.155x | +77.15% |
| 2012-03-31 | Rs987.06 Million ≈ $10.67 Million |
Rs86.48 Million ≈ $935.23K |
0.088x | -48.14% |
| 2011-03-31 | Rs970.25 Million ≈ $10.49 Million |
Rs163.91 Million ≈ $1.77 Million |
0.169x | +50.01% |
| 2010-03-31 | Rs931.08 Million ≈ $10.07 Million |
Rs104.85 Million ≈ $1.13 Million |
0.113x | +252.98% |
| 2009-03-31 | Rs325.25 Million ≈ $3.52 Million |
Rs-23.94 Million ≈ $-258.93K |
-0.074x | -109.22% |
| 2008-03-31 | Rs229.75 Million ≈ $2.48 Million |
Rs183.53 Million ≈ $1.98 Million |
0.799x | -- |
About Astec LifeSciences Limited
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maiz… Read more